Cargando…

Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase Activation and Upregulation of Proapoptotic Bcl-2 Proteins

Targeting of MAP kinase pathways by BRAF inhibitors has evolved as a key therapy for BRAF-mutated melanoma. However, it cannot be applied for BRAF-WT melanoma, and also, in BRAF-mutated melanoma, tumor relapse often follows after an initial phase of tumor regression. Inhibition of MAP kinase pathway...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Zhe, Gillissen, Bernhard, Richter, Antje, Sinnberg, Tobias, Schlaak, Max S., Eberle, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002974/
https://www.ncbi.nlm.nih.gov/pubmed/36902392
http://dx.doi.org/10.3390/ijms24054961
_version_ 1784904498930515968
author Peng, Zhe
Gillissen, Bernhard
Richter, Antje
Sinnberg, Tobias
Schlaak, Max S.
Eberle, Jürgen
author_facet Peng, Zhe
Gillissen, Bernhard
Richter, Antje
Sinnberg, Tobias
Schlaak, Max S.
Eberle, Jürgen
author_sort Peng, Zhe
collection PubMed
description Targeting of MAP kinase pathways by BRAF inhibitors has evolved as a key therapy for BRAF-mutated melanoma. However, it cannot be applied for BRAF-WT melanoma, and also, in BRAF-mutated melanoma, tumor relapse often follows after an initial phase of tumor regression. Inhibition of MAP kinase pathways downstream at ERK1/2, or inhibitors of antiapoptotic Bcl-2 proteins, such as Mcl-1, may serve as alternative strategies. As shown here, the BRAF inhibitor vemurafenib and the ERK inhibitor SCH772984 showed only limited efficacy in melanoma cell lines, when applied alone. However, in combination with the Mcl-1 inhibitor S63845, the effects of vemurafenib were strongly enhanced in BRAF-mutated cell lines, and the effects of SCH772984 were enhanced in both BRAF-mutated and BRAF-WT cells. This resulted in up to 90% loss of cell viability and cell proliferation, as well as in induction of apoptosis in up to 60% of cells. The combination of SCH772984/S63845 resulted in caspase activation, processing of poly (ADP-ribose) polymerase (PARP), phosphorylation of histone H2AX, loss of mitochondrial membrane potential, and cytochrome c release. Proving the critical role of caspases, a pan-caspase inhibitor suppressed apoptosis induction, as well as loss of cell viability. As concerning Bcl-2 family proteins, SCH772984 enhanced expression of the proapoptotic Bim and Puma, as well as decreased phosphorylation of Bad. The combination finally resulted in downregulation of antiapoptotic Bcl-2 and enhanced expression of the proapoptotic Noxa. In conclusion, combined inhibition of ERK and Mcl-1 revealed an impressive efficacy both in BRAF-mutated and WT melanoma cells, and may thus represent a new strategy for overcoming drug resistance.
format Online
Article
Text
id pubmed-10002974
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100029742023-03-11 Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase Activation and Upregulation of Proapoptotic Bcl-2 Proteins Peng, Zhe Gillissen, Bernhard Richter, Antje Sinnberg, Tobias Schlaak, Max S. Eberle, Jürgen Int J Mol Sci Article Targeting of MAP kinase pathways by BRAF inhibitors has evolved as a key therapy for BRAF-mutated melanoma. However, it cannot be applied for BRAF-WT melanoma, and also, in BRAF-mutated melanoma, tumor relapse often follows after an initial phase of tumor regression. Inhibition of MAP kinase pathways downstream at ERK1/2, or inhibitors of antiapoptotic Bcl-2 proteins, such as Mcl-1, may serve as alternative strategies. As shown here, the BRAF inhibitor vemurafenib and the ERK inhibitor SCH772984 showed only limited efficacy in melanoma cell lines, when applied alone. However, in combination with the Mcl-1 inhibitor S63845, the effects of vemurafenib were strongly enhanced in BRAF-mutated cell lines, and the effects of SCH772984 were enhanced in both BRAF-mutated and BRAF-WT cells. This resulted in up to 90% loss of cell viability and cell proliferation, as well as in induction of apoptosis in up to 60% of cells. The combination of SCH772984/S63845 resulted in caspase activation, processing of poly (ADP-ribose) polymerase (PARP), phosphorylation of histone H2AX, loss of mitochondrial membrane potential, and cytochrome c release. Proving the critical role of caspases, a pan-caspase inhibitor suppressed apoptosis induction, as well as loss of cell viability. As concerning Bcl-2 family proteins, SCH772984 enhanced expression of the proapoptotic Bim and Puma, as well as decreased phosphorylation of Bad. The combination finally resulted in downregulation of antiapoptotic Bcl-2 and enhanced expression of the proapoptotic Noxa. In conclusion, combined inhibition of ERK and Mcl-1 revealed an impressive efficacy both in BRAF-mutated and WT melanoma cells, and may thus represent a new strategy for overcoming drug resistance. MDPI 2023-03-04 /pmc/articles/PMC10002974/ /pubmed/36902392 http://dx.doi.org/10.3390/ijms24054961 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Peng, Zhe
Gillissen, Bernhard
Richter, Antje
Sinnberg, Tobias
Schlaak, Max S.
Eberle, Jürgen
Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase Activation and Upregulation of Proapoptotic Bcl-2 Proteins
title Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase Activation and Upregulation of Proapoptotic Bcl-2 Proteins
title_full Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase Activation and Upregulation of Proapoptotic Bcl-2 Proteins
title_fullStr Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase Activation and Upregulation of Proapoptotic Bcl-2 Proteins
title_full_unstemmed Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase Activation and Upregulation of Proapoptotic Bcl-2 Proteins
title_short Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase Activation and Upregulation of Proapoptotic Bcl-2 Proteins
title_sort enhanced apoptosis and loss of cell viability in melanoma cells by combined inhibition of erk and mcl-1 is related to loss of mitochondrial membrane potential, caspase activation and upregulation of proapoptotic bcl-2 proteins
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10002974/
https://www.ncbi.nlm.nih.gov/pubmed/36902392
http://dx.doi.org/10.3390/ijms24054961
work_keys_str_mv AT pengzhe enhancedapoptosisandlossofcellviabilityinmelanomacellsbycombinedinhibitionoferkandmcl1isrelatedtolossofmitochondrialmembranepotentialcaspaseactivationandupregulationofproapoptoticbcl2proteins
AT gillissenbernhard enhancedapoptosisandlossofcellviabilityinmelanomacellsbycombinedinhibitionoferkandmcl1isrelatedtolossofmitochondrialmembranepotentialcaspaseactivationandupregulationofproapoptoticbcl2proteins
AT richterantje enhancedapoptosisandlossofcellviabilityinmelanomacellsbycombinedinhibitionoferkandmcl1isrelatedtolossofmitochondrialmembranepotentialcaspaseactivationandupregulationofproapoptoticbcl2proteins
AT sinnbergtobias enhancedapoptosisandlossofcellviabilityinmelanomacellsbycombinedinhibitionoferkandmcl1isrelatedtolossofmitochondrialmembranepotentialcaspaseactivationandupregulationofproapoptoticbcl2proteins
AT schlaakmaxs enhancedapoptosisandlossofcellviabilityinmelanomacellsbycombinedinhibitionoferkandmcl1isrelatedtolossofmitochondrialmembranepotentialcaspaseactivationandupregulationofproapoptoticbcl2proteins
AT eberlejurgen enhancedapoptosisandlossofcellviabilityinmelanomacellsbycombinedinhibitionoferkandmcl1isrelatedtolossofmitochondrialmembranepotentialcaspaseactivationandupregulationofproapoptoticbcl2proteins